Verrica Pharmaceuticals Inc (NASDAQ: VRCA) is -84.84% lower on its value in year-to-date trading and has touched a low of $1.36 and a high of $11.41 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VRCA stock was last observed hovering at around $1.37 in the last trading session, with the day’s loss setting it -0.26%.
Currently trading at $1.11, the stock is -39.36% and -67.74% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.5 million and changing -18.98% at the moment leaves the stock -81.16% off its SMA200. VRCA registered -72.32% loss for a year compared to 6-month loss of -81.98%. The firm has a 50-day simple moving average (SMA 50) of $3.313 and a 200-day simple moving average (SMA200) of $5.87835.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -49.08% gain in the last 1 month and extending the period to 3 months gives it a -85.20%, and is -33.13% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.13% over the week and 9.76% over the month.
Verrica Pharmaceuticals Inc (VRCA) has around 100 employees, a market worth around $47.36M and $13.91M in sales. Profit margin for the company is -625.06%. Distance from 52-week low is -18.38% and -90.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-272.01%).
The EPS is expected to grow by 0.91% this year
101.0 institutions hold shares in Verrica Pharmaceuticals Inc (VRCA), with institutional investors hold 66.60% of the company’s shares. The shares outstanding are 42.41M, and float is at 26.07M with Short Float at 12.48%. Institutions hold 43.78% of the Float.
The top institutional shareholder in the company is PERCEPTIVE ADVISORS LLC with over 7.1 million shares valued at $51.75 million. The investor’s holdings represent 15.2724 of the VRCA Shares outstanding. As of 2024-06-30, the second largest holder is AVORO CAPITAL ADVISORS LLC with 4.0 million shares valued at $29.16 million to account for 8.6052 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 1.27 million shares representing 2.731 and valued at over $9.25 million, while BLACKROCK INC. holds 2.4291 of the shares totaling 1.13 million with a market value of $8.23 million.
Verrica Pharmaceuticals Inc (VRCA) Insider Activity
The most recent transaction is an insider sale by Hayes Christopher G., the company’s CHIEF LEGAL OFFICER. SEC filings show that Hayes Christopher G. sold 26,183 shares of the company’s common stock on Aug 26 ’24 at a price of $2.66 per share for a total of $69647.0. Following the sale, the insider now owns 0.12 million shares.
Verrica Pharmaceuticals Inc disclosed in a document filed with the SEC on Aug 27 ’24 that Hayes Christopher G. (CHIEF LEGAL OFFICER) sold a total of 9,530 shares of the company’s common stock. The trade occurred on Aug 27 ’24 and was made at $2.46 per share for $23444.0. Following the transaction, the insider now directly holds 0.11 million shares of the VRCA stock.
Still, SEC filings show that on Aug 26 ’24, Goldenberg Gary (Chief Medical Officer) disposed off 9,888 shares at an average price of $2.66 for $26302.0. The insider now directly holds 97,862 shares of Verrica Pharmaceuticals Inc (VRCA).
